- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
OKYO Pharma is planning meetings with the FDA regarding next steps for its clinical trials being conducted in Boston.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
OKYO Pharma is planning meetings with the FDA regarding next steps for its clinical trials being conducted in Boston.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- An AI software company based in Baltimore is seeking FDA clearance and planning a clinic pilot in New Orleans.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- GlobeNewswireOKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed gr